ES2398434T8 - Isómeros ópticos de un metabolito de iloperidona - Google Patents

Isómeros ópticos de un metabolito de iloperidona Download PDF

Info

Publication number: ES2398434T8
Authority: ES; Spain
Prior art keywords: optical isomers; iloperidone metabolite; fouoro; isoxazol; piperidin
Prior art date: 2001-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES10009915.9T

Other languages

English (en)

Other versions

ES2398434T3 (es

Inventor

Dominique Grimler

Hans O. Kalkman

Hequn Yin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-31

Filing date

2002-08-30

Publication date

2017-10-09

2002-08-30 Application filed by Novartis AG filed Critical Novartis AG

2013-03-19 Application granted granted Critical

2013-03-19 Publication of ES2398434T3 publication Critical patent/ES2398434T3/es

2017-10-09 Publication of ES2398434T8 publication Critical patent/ES2398434T8/es

2022-08-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
230000003287 optical effect Effects 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

ES10009915T 2001-08-31 2002-08-30 Isómeros ópticos de un metabolito de iloperidona Expired - Lifetime ES2398434T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31639001P	2001-08-31	2001-08-31
US316390P		2001-08-31

Publications (2)

Publication Number	Publication Date
ES2398434T3 ES2398434T3 (es)	2013-03-19
ES2398434T8 true ES2398434T8 (es)	2017-10-09

Family

ID=23228843

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES10009915T Expired - Lifetime ES2398434T3 (es)	2001-08-31	2002-08-30	Isómeros ópticos de un metabolito de iloperidona
ES02767454T Expired - Lifetime ES2370634T3 (es)	2001-08-31	2002-08-30	Isómeros ópticos de un metabolito de iloperidona.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES02767454T Expired - Lifetime ES2370634T3 (es)	2001-08-31	2002-08-30	Isómeros ópticos de un metabolito de iloperidona.

Country Status (9)

Country	Link
US (4)	US20050020632A1 (es)
EP (2)	EP2305656B1 (es)
JP (6)	JP2005504783A (es)
AT (1)	ATE518845T1 (es)
CY (2)	CY1112039T1 (es)
DK (2)	DK2305656T3 (es)
ES (2)	ES2398434T3 (es)
PT (2)	PT2305656E (es)
WO (1)	WO2003020707A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0213564B8 (pt)	2001-10-30	2021-05-25	Novartis Ag	formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
RU2309154C9 (ru)	2002-03-27	2016-09-27	Глэксо Груп Лимитед	3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
GB0216416D0 (en) *	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
DE602004000260T2 (de)	2003-07-22	2006-08-24	Arena Pharmaceuticals, Inc., San Diego	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0322994D0 (en) *	2003-10-01	2003-11-05	Novartis Ag	Organic compounds
US20100063093A1 (en) *	2007-03-28	2010-03-11	Curt Wolfgang	Methods for the administration of iloperidone
WO2006039663A2 (en)	2004-09-30	2006-04-13	Vanda Pharmaceuticals, Inc	Methods for the administration of iloperidone
US8008144B2 (en)	2006-05-11	2011-08-30	Micron Technology, Inc.	Dual work function recessed access device and methods of forming
US20070262395A1 (en)	2006-05-11	2007-11-15	Gibbons Jasper S	Memory cell access devices and methods of making the same
US20090306137A1 (en)	2006-05-22	2009-12-10	Wolfgang Curt D	Treatment for depressive disorders
US20150259747A1 (en)	2007-03-29	2015-09-17	Vanda Pharmaceuticals Inc.	Method of predicting a predisposition to qt prolongation
WO2008121899A2 (en)	2007-03-29	2008-10-09	Vanda Pharmaceuticals Inc.	Method of predicting a predisposition to qt prolongation
US8198305B2 (en)	2007-04-13	2012-06-12	Concert Pharmaceuticals Inc.	1,2-benzisoxazol-3-yl compounds
WO2008144599A2 (en)	2007-05-18	2008-11-27	Vanda Pharmaceuticals Inc.	Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
CA2698534C (en)	2007-09-10	2018-10-09	Vanda Pharmaceuticals, Inc.	Prediction of qt prolongation based on snp genotype
EP2508177A1 (en)	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009076664A1 (en)	2007-12-13	2009-06-18	Vanda Pharmaceuticals Inc.	Method and composition for treating a serotonin receptor-mediated condition
EP2222301B1 (en) *	2007-12-13	2014-10-08	Vanda Pharmaceuticals Inc.	Method and composition for treating an alpha adrenoceptor-mediated condition
US20110061014A1 (en)	2008-02-01	2011-03-10	Energyhub	Interfacing to resource consumption management devices
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en)	2008-11-05	2010-11-02	Micron Technology, Inc.	Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
JP5881597B2 (ja)	2009-04-06	2016-03-09	ヴァンダファーマシューティカルズインコーポレイテッド	Ｑｔ延長に対する素因を予測する方法
US9072742B2 (en)	2009-04-06	2015-07-07	Vanda Pharmaceuticals, Inc.	Method of predicting a predisposition to QT prolongation
US9074256B2 (en)	2009-04-06	2015-07-07	Vanda Pharmaceuticals, Inc.	Method of predicting a predisposition to QT prolongation
WO2010117931A1 (en)	2009-04-06	2010-10-14	Vanda Pharmaceuticals, Inc.	Method of treatment based on polymorphisms of the kcnq1 gene
BR112012015084A2 (pt)	2009-12-23	2017-03-07	Lupin Ltd	composição farmacêutica de liberação lenta de iloperidone
US9000221B2 (en)	2010-09-07	2015-04-07	Symed Labs Limited	Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en)	2010-11-12	2012-05-18	Cadila Healthcare Limited	Process for preparing iloperidone
CA2865845C (en) *	2012-03-14	2020-02-18	Vanda Pharmaceuticals Inc.	An iloperidone metabolite for use in the treatment of psychiatric disorders
ES2870498T3 (es)	2015-02-17	2021-10-27	Vanda Pharmaceuticals Inc	Iloperidona para el tratamiento de esquizofrenia
US10022355B2 (en)	2015-06-12	2018-07-17	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt)	2015-07-15	2018-09-04	Axovant Sciences Gmbh	resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
IL285721B2 (en) *	2019-02-21	2025-03-01	Obi Pharma Inc	Methods of making high enantioselective secondary alcohols
US11607408B2 (en)	2019-10-15	2023-03-21	Vanda Pharmaceuticals Inc.	Method of treatment of schizophrenia
EP4507698A1 (en)	2022-04-13	2025-02-19	Vanda Pharmaceuticals Inc.	Treatment of parkinson's disease and parkinson's disease psychosis
AU2023408198A1 (en)	2022-12-19	2025-05-29	Vanda Pharmaceuticals Inc.	Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
IL324466A (en)	2023-06-02	2026-01-01	Vanda Pharmaceuticals Inc	Method of treatment with iloperidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4804663A (en) *	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) *	1988-11-07	1992-10-27	Janssen Pharmaceutica N.V.	3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
DE69021645T2 (de) *	1989-05-19	1996-02-22	Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.	N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5364866A (en) *	1989-05-19	1994-11-15	Hoechst-Roussel Pharmaceuticals, Inc.	Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en)	1989-05-19	1998-07-07	Hoechst Marion Roussel, Inc.	3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
JPH05286868A (ja)	1992-04-03	1993-11-02	Kiyoshi Okawa	制がん剤複合体およびそのスクリーニング法
US5889006A (en) *	1995-02-23	1999-03-30	Schering Corporation	Muscarinic antagonists
ES2149742T1 (es) *	1997-07-03	2000-11-16	Asahi Chemical Ind	Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos.
CA2529857A1 (en)	2002-07-30	2004-02-05	Peter Migaly	Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

2002
- 2002-08-30 JP JP2003524978A patent/JP2005504783A/ja not_active Withdrawn
- 2002-08-30 PT PT100099159T patent/PT2305656E/pt unknown
- 2002-08-30 PT PT02767454T patent/PT1425272E/pt unknown
- 2002-08-30 ES ES10009915T patent/ES2398434T3/es not_active Expired - Lifetime
- 2002-08-30 AT AT02767454T patent/ATE518845T1/de active
- 2002-08-30 ES ES02767454T patent/ES2370634T3/es not_active Expired - Lifetime
- 2002-08-30 EP EP10009915A patent/EP2305656B1/en not_active Expired - Lifetime
- 2002-08-30 US US10/488,128 patent/US20050020632A1/en not_active Abandoned
- 2002-08-30 DK DK10009915.9T patent/DK2305656T3/da active
- 2002-08-30 DK DK02767454.8T patent/DK1425272T3/da active
- 2002-08-30 EP EP02767454A patent/EP1425272B1/en not_active Expired - Lifetime
- 2002-08-30 WO PCT/EP2002/009700 patent/WO2003020707A1/en not_active Ceased
2009
- 2009-03-13 US US12/403,755 patent/US7977356B2/en not_active Expired - Lifetime
- 2009-12-11 JP JP2009281094A patent/JP2010100633A/ja not_active Withdrawn
2011
- 2011-04-28 US US13/096,015 patent/US8314129B2/en not_active Expired - Lifetime
- 2011-11-02 CY CY20111101053T patent/CY1112039T1/el unknown
2012
- 2012-10-26 US US13/661,609 patent/US20130296366A1/en not_active Abandoned
2013
- 2013-01-23 CY CY20131100058T patent/CY1113550T1/el unknown
- 2013-01-31 JP JP2013017050A patent/JP2013116905A/ja not_active Withdrawn
- 2013-07-08 JP JP2013142873A patent/JP2013227335A/ja active Pending
2015
- 2015-08-06 JP JP2015156359A patent/JP2015214577A/ja active Pending
- 2015-08-06 JP JP2015156358A patent/JP2015227368A/ja active Pending

Also Published As

Publication number	Publication date
US20090176739A1 (en)	2009-07-09
EP2305656B1 (en)	2012-10-24
CY1113550T1 (el)	2016-06-22
DK2305656T3 (da)	2013-02-11
US20130296366A1 (en)	2013-11-07
ES2398434T3 (es)	2013-03-19
JP2010100633A (ja)	2010-05-06
JP2013116905A (ja)	2013-06-13
US20110201646A1 (en)	2011-08-18
DK1425272T3 (da)	2011-11-21
HK1156309A1 (en)	2012-09-07
HK1066536A1 (en)	2005-03-24
PT1425272E (pt)	2011-10-19
ATE518845T1 (de)	2011-08-15
JP2015227368A (ja)	2015-12-17
EP1425272A1 (en)	2004-06-09
EP1425272B1 (en)	2011-08-03
PT2305656E (pt)	2013-01-10
ES2370634T3 (es)	2011-12-21
US8314129B2 (en)	2012-11-20
JP2005504783A (ja)	2005-02-17
WO2003020707A1 (en)	2003-03-13
JP2015214577A (ja)	2015-12-03
CY1112039T1 (el)	2015-11-04
EP2305656A1 (en)	2011-04-06
JP2013227335A (ja)	2013-11-07
US20050020632A1 (en)	2005-01-27
US7977356B2 (en)	2011-07-12

Publication	Publication Date	Title
ES2398434T8 (es)	2017-10-09	Isómeros ópticos de un metabolito de iloperidona
NO20051965D0 (no)	2005-04-22	Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
DE502004009532D1 (de)	2009-07-09	Fungizide ternäre wirkstoffkombinationen
NO20050429L (no)	2005-03-29	Substituert kinolin-CCR5-reseptorantagonister
PE20080360A1 (es)	2008-05-22	Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
NO20076498L (no)	2008-02-20	Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
NO20073366L (no)	2007-09-21	1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose
HRP20110640T1 (hr)	2011-10-31	Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava
HRP20080446T3 (en)	2008-10-31	Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
ATE512961T1 (de)	2011-07-15	Amorphes nebivolol hydrochlorid und seine herstellung
NO20075022L (no)	2007-10-04	(7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
ATE455103T1 (de)	2010-01-15	Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE602004016850D1 (de)	2008-11-13	Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
NO20065327L (no)	2006-12-18	Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
DE602004009079D1 (de)	2007-10-31	Carbostyril-derivative zur beschleunigten speichelabsonderung
DE60225694D1 (de)	2008-04-30	Fexofenadine hydrochlorid polymorph
NO20070972L (no)	2007-02-28	Benzyloksyderivater som MAOB-inhibitorer
EA200401290A1 (ru)	2005-02-24	НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa
DE602006010329D1 (de)	2009-12-24	Verfahren zur herstellung eines indolon-derivats
SE0102809D0 (sv)	2001-08-22	Novel compounds
UY31400A1 (es)	2009-05-29	Composiciones farmaceuticas
HRP20030653B1 (en)	2012-06-30	Novel benzoylguanidine salt
AR026673A1 (es)	2003-02-19	Benzoilpirazoles sustituidos por 3-(4,5-dihidroisoxazol-3-ilo)
HN2005000205A (es)	2009-10-30	Compuestos terapeuticos
NO20056188L (no)	2005-12-23	Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes